See how EMET supports clinical teams focused on therapy safety, evidence review, and decision support.
Clinical capabilities
Explore a range of sample prompts and representative outputs from EMET across the workflows below.
Our new JAK2 inhibitor will be co-administered with warfarin, omeprazole, sertraline, and metoprolol in elderly oncology patients. Run a comprehensive DDI screen and flag major interactions with mechanistic explanation.
Assess the clinical evidence and safety profile for KRAS G12C inhibitors in non-small cell lung cancer - summarize approved therapies, ongoing trials, known resistance mechanisms, and any pharmacogenomic considerations.
Analyse FAERS data for the SGLT2 inhibitor class (canagliflozin, dapagliflozin, empagliflozin). Quantify the signal strength for Fournier's gangrene, DKA, and amputation risk using PRR/ROR statistics, show temporal trends since approval, and compare signal magnitude across agents.
Identify genomic and transcriptomic biomarkers that could stratify HER2-low breast cancer patients most likely to respond to trastuzumab deruxtecan (T-DXd), and assess the evidence supporting each biomarker's clinical utility.
Generate a comprehensive comparative safety profile for all three approved CDK4/6 inhibitors - palbociclib, ribociclib, and abemaciclib - across FAERS signal data, FDA label warnings, and Grade 3/4 AE rates from their pivotal Phase III trials. Identify any meaningful safety differentiation.
OpenFDA / FAERSDailyMedPubMed trialsMedDRA
Drug programs fail when biology is misunderstood. EMET exists to close that gap — before it closes your pipeline.
